<DOC>
	<DOCNO>NCT02116998</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study . Eligible subject randomize 1:1 ratio receive GEN-004 adjuvant placebo . Each subject receive 3 dos 4 week interval . Following third dose , subject inoculate intranasally S. pneumoniae serotype 6B . Nasal wash identify S. pneumoniae colonization obtain pre-inoculation , 2 , 7 14 day inoculation . Subjects also monitor safety tolerability throughout dose period , 12 month last dose . The purpose study evaluate effectiveness GEN-004 reduce colonization rate magnitude colonization follow S. pneumoniae challenge .</brief_summary>
	<brief_title>Safety , Tolerability , Efficacy Study Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Pneumonia , Pneumococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Males nonpregnant female , age 18 55 year inclusive . Willing able provide write informed consent . Fluent English speaker ( safety reason ) Willing perform comply study procedure include attend clinic visit schedule . Prior vaccination pneumococcal vaccine . History invasive pneumococcal disease ( i.e. , sepsis , meningitis pneumonia bacteremia ) . Close contact risk individual ( young child [ 5years ] , immunosuppressed adult , elderly , chronic ill health ) . Current smoker significant smoking history ( &gt; 10 pack year ) . Pregnant breastfeed woman . Women childbearing potential ( WOCBP ) deem sufficient , effective birth control place 1 month prior vaccination 1 month final vaccination . Allergy penicillin amoxicillin . Any screen laboratory value &gt; Grade 1 Positive serologic test HIV1 hepatitis C infection ; positive hepatitis B surface antigen ( HBsAg ) . Asthma ( regular medication ) respiratory disease . Immunocompromised individual , include receive corticosteroid immunosuppressive agent . Presence history autoimmune disease ( refer Appendix 4 ) regardless current treatment . No antibiotic treatment within 1 week inoculation Previous involvement EHPC study inoculate pneumococcal bacteria In clinical trial unless observational stage followup Diabetes , type 1 type 2 . Other active , uncontrolled comorbidities , opinion Investigator would make subject unsuitable study unable comply study requirement . NOTE : Subjects take medication control underlie comorbidity may enrol change medication within 60 day prior first dose Study Drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>GEN-004</keyword>
	<keyword>Aluminum hydroxide</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Streptococcus pneumoniae</keyword>
	<keyword>Pneumococcal Infections</keyword>
	<keyword>Strep pneumoniae</keyword>
	<keyword>Pneumonia</keyword>
</DOC>